This commentary highlights emerging strategies and challenges in treating newly diagnosed myeloma, suggesting a need for risk-adapted approaches.
This commentary explores new challenges in the management of newly diagnosed multiple myeloma and strategies for sustaining improvements in patient outcomes. We highlight the need for risk-adapted approaches, the potential future incorporation of T cell-redirecting immunotherapies in first-line treatment, and the challenge of access to care.
No takes yet. Share an insight, caveat, or question.
Touzeau et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: